Introduction: Growth Hormone Secretagogues
Growth hormone secretagogues (GHS) are a class of synthetic peptides and small molecules that stimulate growth hormone (GH) secretion from anterior pituitary somatotroph cells through mechanisms distinct from hypothalamic growth hormone-releasing hormone (GHRH). The discovery of ghrelin (Kojima et al., 1999, Nature) as the endogenous GHS-R1a ligand provided a mechanistic framework for understanding GHS pharmacology — a field initiated by the serendipitous observation that Met-enkephalin analogs stimulated GH secretion in vitro (Bowers et al., 1977, Endocrinology).
Ipamorelin (NNC 26-0161; AIBUNORF-NH₂ in older literature; sequence: Aib-His-d-2-Nal-d-Phe-Lys-NH₂) is a pentapeptide GHS characterized by exceptional receptor selectivity for GHS-R1a over other neuropeptide receptors, distinguishing it from earlier generation compounds such as GHRP-6 and hexarelin.
All content is for research purposes only. Not for human consumption.
GHS-R1a: Structure and Signaling
Receptor Architecture
GHS-R1a (Growth Hormone Secretagogue Receptor 1a; gene: GHSR; UniProt Q92847) is a 366-amino-acid, seven-transmembrane GPCR that constitutes the prototypic peptide-gated growth hormone secretagogue receptor. Key structural features include:
- An extended extracellular N-terminus and loops ECL2/ECL3 that form the orthosteric ligand-binding pocket.
- A conserved DRY (Asp-Arg-Tyr) motif at the TM3/intracellular loop 2 junction, critical for G protein coupling.
- High constitutive activity (~50% of maximal activation in the absence of ligand), attributable to a rare Ala204–Ser203 interaction within the transmembrane bundle stabilizing an active-like conformation (Holst et al., 2003, Molecular Endocrinology).
Downstream Signal Transduction
GHS-R1a activates dual G protein coupling:
- Gαq/11 (primary pathway in somatotrophs): PLCβ1 activation → IP₃ production → InsP₃R-mediated ER Ca²⁺ release → calmodulin/calmodulin-dependent kinase II (CaMKII) activation → GH vesicle exocytosis.
- Gα11/Gα12: Rho GEF activation → RhoA/ROCK → cytoskeletal reorganization contributing to somatotroph morphological changes.
- Gαi/o: At non-pituitary GHS-R1a expression sites (hypothalamic NPY/AgRP neurons), Gαi coupling reduces cAMP and modulates GIRK channel conductance.
- β-Arrestin recruitment: GHS-R1a undergoes GRK2/3-mediated phosphorylation at Ser/Thr residues on intracellular loops 3 and C-terminus, recruiting β-arrestin-1/2 for desensitization and ERK1/2 activation from endosomal platforms.
IP₃-mediated Ca²⁺ release acts synergistically with simultaneous GHRH-mediated cAMP elevation in somatotrophs — the two pathways converge on PKA-mediated phosphorylation of synapsin and VAMP2 (vesicle-associated membrane protein 2), facilitating GH secretory granule docking and fusion at the plasma membrane.
Ipamorelin Structure–Activity Relationships
Non-Natural Amino Acid Content
Ipamorelin's pentapeptide sequence incorporates several structural elements that confer selectivity and stability:
- Aib (α-aminoisobutyric acid) at position 1: Geminal dimethyl substitution of glycine imposes steric restriction on φ/ψ backbone dihedrals, nucleating helical turn geometry and conferring aminopeptidase resistance.
- d-2-Naphthylalanine (d-2-Nal) at position 3: The aromatic naphthyl side chain engages a hydrophobic pocket within the GHS-R1a orthosteric site critical for agonist efficacy; the d-configuration optimizes binding geometry.
- d-Phenylalanine at position 4: d-stereochemistry at this position is essential for receptor affinity; l-Phe substitution reduces potency by ~100-fold in receptor binding assays.
- Lys-NH₂ C-terminal amide: C-terminal amidation prevents carboxypeptidase attack and contributes to receptor contact.
Binding Affinity and Functional Potency
Radioligand competition binding assays using [125I]Tyr-Ala-hexarelin in rat pituitary membranes established ipamorelin's Ki of approximately 1.0 nM for GHS-R1a, comparable to GHRP-6 and ghrelin. Functional cAMP and calcium mobilization assays in GHS-R1a-transfected COS-7 and HEK293 cells demonstrate EC₅₀ values of 1–3 nM with full agonist efficacy relative to ghrelin (Raun et al., 1998, European Journal of Endocrinology).
Selectivity Profile: Differentiating Ipamorelin
The defining pharmacological attribute of ipamorelin is its high selectivity for GHS-R1a over other neuropeptide receptors that are co-stimulated by earlier generation GHS compounds:
Cortisol/ACTH Release
GHRP-6 and hexarelin demonstrate significant cortisol and ACTH release in vivo — attributed to off-target engagement of hypothalamic corticotropin-releasing hormone (CRH) receptors or direct pituitary corticotroph stimulation. Ipamorelin shows no measurable cortisol, ACTH, or FSH/LH release at doses 500-fold above the GH-stimulating dose in rat research models (Raun et al., 1998), a selectivity advantage enabling more precise investigation of somatotroph pharmacology.
Prolactin Release
Hexarelin and GHRP-2 stimulate significant prolactin secretion through dopamine D₂ receptor antagonism in lactotrophs. Ipamorelin produces negligible prolactin release at GH-effective concentrations, consistent with absence of dopaminergic activity in receptor panel screening.
Ghrelin Receptor Panel
Receptor binding panels at 1 µM ipamorelin against 70+ GPCRs, ion channels, and enzymes demonstrate selectivity ratios of >1000-fold for GHS-R1a over the nearest off-target receptor, classifying ipamorelin as a highly selective tool compound for GHS-R1a pathway research.
Hypothalamic Interactions: GHRH Synergy
GHS-R1a is expressed on hypothalamic GHRH-secreting neurons in the arcuate nucleus (ARC) and ventromedial hypothalamus. GHS-R1a agonism at this level amplifies pulsatile GHRH release, creating a supra-pituitary amplification cascade. In vitro co-stimulation paradigms combining ipamorelin with GHRH demonstrate super-additive GH release responses in rat pituitary cell cultures, consistent with convergent Gαq (ipamorelin) + Gαs (GHRH) signaling on the same somatotroph secretory machinery.
Somatostatin Axis Interactions
Somatostatin (SRIF-14 and SRIF-28) is the primary physiological inhibitor of GH secretion, signaling through five receptor subtypes (SSTR1–5) that couple predominantly to Gαi, reducing cAMP and activating K⁺ channels to hyperpolarize somatotrophs. GHS-R1a agonism by ipamorelin partially overcomes somatostatin inhibition through Gαq-mediated Ca²⁺ elevation, which can drive GH exocytosis even under conditions of reduced cAMP. This functional antagonism of somatostatin-mediated inhibition is observable in in vivo research paradigms using somatostatin infusion models.
GHS-R1b: Truncated Receptor Isoform
Alternative splicing of the GHSR gene produces GHS-R1b, a five-transmembrane truncated receptor isoform. GHS-R1b lacks the full orthosteric binding site and does not respond to ipamorelin or ghrelin. However, GHS-R1b can heterodimerize with GHS-R1a and with dopamine D1R, modulating GHS-R1a signaling efficiency and cell-surface trafficking. This receptor heterodimer biology adds mechanistic complexity relevant to GHS-R1a pathway research in tissues co-expressing both isoforms.
Research Availability
Lumevara offers Ipamorelin as a research-grade lyophilized peptide for laboratory use. All material includes third-party CoA with RP-HPLC purity ≥98% and ESI-MS confirmation. For information on related growth hormone secretagogue research tools, see our Muscle Support research category.
Disclaimer: For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.